On March 16, 2026, Simcere Pharmaceutical Group (2096.HK) announced that the Phase 3 clinical trial of deuremidevir hydrobromide dry suspension (devel...

On February 2, 2026, Simcere Pharmaceutical Group (2096.HK) announced that its thrombolytic candidate drug for stroke, SIM0811, has recently initiated...

•Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. • Li...

January 20 2026， Simcere Zaiming, an oncology-focused bipharmaceutical company and a subsidiary of Simcere Pharmaceutical Group (2096.HK) announced to...